NewAmsterdam Pharma (NAMS) Equity Average (2023 - 2025)
Historic Equity Average for NewAmsterdam Pharma (NAMS) over the last 3 years, with Q3 2025 value amounting to $753.3 million.
- NewAmsterdam Pharma's Equity Average rose 9660.25% to $753.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $753.3 million, marking a year-over-year increase of 9660.25%. This contributed to the annual value of $522.9 million for FY2024, which is 4557.45% up from last year.
- NewAmsterdam Pharma's Equity Average amounted to $753.3 million in Q3 2025, which was up 9660.25% from $777.9 million recorded in Q2 2025.
- Over the past 5 years, NewAmsterdam Pharma's Equity Average peaked at $777.9 million during Q2 2025, and registered a low of $310.1 million during Q4 2023.
- Its 3-year average for Equity Average is $499.5 million, with a median of $399.6 million in 2024.
- Per our database at Business Quant, NewAmsterdam Pharma's Equity Average tumbled by 2156.78% in 2024 and then soared by 11920.48% in 2025.
- Quarter analysis of 3 years shows NewAmsterdam Pharma's Equity Average stood at $310.1 million in 2023, then soared by 83.22% to $568.2 million in 2024, then skyrocketed by 32.58% to $753.3 million in 2025.
- Its Equity Average was $753.3 million in Q3 2025, compared to $777.9 million in Q2 2025 and $767.4 million in Q1 2025.